PanTarg is a biotechnology company developing a new generation of antibody-drug conjugates (ADCs) with broad pan-cancer potential, initially targeting pancreatic cancer. Its approach combines targeted delivery to cancer cells with a strategy to dismantle the tumor-supporting stroma, making tumors more vulnerable to treatment. The lead program focuses on one of the most challenging and underserved cancer types.
Funding
€1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pancreatic cancer remains one of the most challenging and underserved cancer types, with limited treatment options and poor patient outcomes. The tumor-supporting stroma creates a physical and biochemical barrier that reduces the effectiveness of conventional therapies, including antibody-drug conjugates.
Solution
PanTarg is advancing a new generation of antibody-drug conjugates (ADCs) with broad pan-cancer potential. The company's approach combines targeted delivery to cancer cells with a unique strategy to dismantle the tumor-supporting stroma, thereby making tumors more vulnerable to treatment. By addressing both the cancer cells and the protective tumor microenvironment, PanTarg aims to improve the efficacy of ADC therapy and ultimately enhance patient outcomes. The lead program is specifically focused on pancreatic cancer, where this dual mechanism could have significant impact.
Target Audience
Primary customers are oncology drug developers and clinical partners seeking more effective treatments for pancreatic cancer and other solid tumors with dense stromal environments.
Features
- ADC platform with broad pan-cancer potential beyond a single tumor type
- Dual mechanism targeting both cancer cells and tumor-supporting stroma
- Lead program specifically developed for pancreatic cancer
- Strategy designed to dismantle stromal barriers that limit treatment efficacy
- Built on extensive research into pancreatic cancer biology and ADC development